Last 12 months
Inside the activity.
0 purchase rows · 214 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 14 |
| Dec 2025 | 0 | 10 |
| Jan 2026 | 0 | 3 |
| Feb 2026 | 0 | 3 |
| Mar 2026 | 0 | 26 |
| Apr 2026 | 0 | 14 |
| May 2026 | 0 | 28 |
| Jun 2026 | 0 | 15 |
| Jul 2026 | 0 | 36 |
| Aug 2026 | 0 | 44 |
| Sep 2026 | 0 | 15 |
| Oct 2026 | 0 | 6 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 26, 2021 Filed Jan 27, 2021 21:11 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 1,540 | $70.79 | $109,016.60 |
DisclosureSEC source: 0001447362-21-000018 · wf-form4_161178186829884.xml · nonDerivative · entry 7 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 386,953 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F9 · price: This transaction was executed in multiple trades at prices ranging from $70.570 to $71.335, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 21:11 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 700 | $80.50 | $56,348.60 |
DisclosureSEC source: 0001447362-21-000018 · wf-form4_161178186829884.xml · nonDerivative · entry 6 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 388,493 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F8 · price: This transaction was executed in multiple trades at prices ranging from $80.180 to $80.810, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 21:11 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 1,010 | $79.70 | $80,495.99 |
DisclosureSEC source: 0001447362-21-000018 · wf-form4_161178186829884.xml · nonDerivative · entry 5 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 389,193 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $79.140 to $80.120, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 21:11 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 100 | $78.13 | $7,813.30 |
DisclosureSEC source: 0001447362-21-000018 · wf-form4_161178186829884.xml · nonDerivative · entry 4 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 390,203 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $78.110 to $78.190, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 21:11 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 1,084 | $77.31 | $83,808.38 |
DisclosureSEC source: 0001447362-21-000018 · wf-form4_161178186829884.xml · nonDerivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 390,303 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $76.880 to $77.710, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 21:11 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 1,800 | $76.32 | $137,383.20 |
DisclosureSEC source: 0001447362-21-000018 · wf-form4_161178186829884.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 391,387 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $75.870 to $76.740, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 21:11 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 2,806 | $75.26 | $211,171.14 |
DisclosureSEC source: 0001447362-21-000018 · wf-form4_161178186829884.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 393,187 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $74.740 to $75.710, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 21:06 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 500 | $77.77 | $38,885.00 |
DisclosureSEC source: 0001447362-21-000016 · wf-form4_161109037611294.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 867,887 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $77.33 to $77.97, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 21:06 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 4,891 | $75.92 | $371,324.72 |
DisclosureSEC source: 0001447362-21-000016 · wf-form4_161109037611294.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 868,387 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $75.63 to $76.53, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 21:06 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 4,647 | $75.10 | $348,989.70 |
DisclosureSEC source: 0001447362-21-000016 · wf-form4_161109037611294.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 873,278 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $74.60 to $75.57, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 21:06 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 4,339 | $73.93 | $320,782.27 |
DisclosureSEC source: 0001447362-21-000016 · wf-form4_161109037611294.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 877,925 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $73.59 to $74.58, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 14, 2021 Filed Jan 15, 2021 21:17 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 1,858 | $76.55 | $142,229.90 |
DisclosureSEC source: 0001447362-21-000014 · wf-form4_161074545857133.xml · nonDerivative · entry 13 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 882,264 F6 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F14 · price: This transaction was executed in multiple trades at prices ranging from $76.33 to $76.93, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 14, 2021 Filed Jan 15, 2021 21:17 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 3,142 | $75.80 | $238,163.60 |
DisclosureSEC source: 0001447362-21-000014 · wf-form4_161074545857133.xml · nonDerivative · entry 12 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 884,122 F6 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F13 · price: This transaction was executed in multiple trades at prices ranging from $75.30 to $76.28, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 14, 2021 Filed Jan 15, 2021 21:17 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 4,618 | $76.52 | $353,369.36 |
DisclosureSEC source: 0001447362-21-000014 · wf-form4_161074545857133.xml · nonDerivative · entry 11 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 887,264 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F12 · price: This transaction was executed in multiple trades at prices ranging from $76.25 to $77.09, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 14, 2021 Filed Jan 15, 2021 21:17 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 4,759 | $75.74 | $360,446.66 |
DisclosureSEC source: 0001447362-21-000014 · wf-form4_161074545857133.xml · nonDerivative · entry 10 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 891,882 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F11 · price: This transaction was executed in multiple trades at prices ranging from $75.25 to $76.24, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 13, 2021 Filed Jan 14, 2021 21:06 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 326 | $74.91 | $24,420.66 |
DisclosureSEC source: 0001447362-21-000012 · wf-form4_161065836982292.xml · nonDerivative · entry 7 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 395,993 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F8 · price: This transaction was executed in multiple trades at prices ranging from $74.55 to $75.13, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| January 13, 2021 Filed Jan 14, 2021 21:06 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 4,597 | $74.01 | $340,223.97 |
DisclosureSEC source: 0001447362-21-000012 · wf-form4_161065836982292.xml · nonDerivative · entry 6 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 396,319 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $73.50 to $74.49, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| January 13, 2021 Filed Jan 14, 2021 21:06 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 2,377 | $72.91 | $173,307.07 |
DisclosureSEC source: 0001447362-21-000012 · wf-form4_161065836982292.xml · nonDerivative · entry 5 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 400,916 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $72.50 to $73.26, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| January 13, 2021 Filed Jan 14, 2021 21:06 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 200 | $71.32 | $14,264.00 |
DisclosureSEC source: 0001447362-21-000012 · wf-form4_161065836982292.xml · nonDerivative · entry 4 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 403,293 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:17 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 611 | $74.56 | $45,556.16 |
DisclosureSEC source: 0001447362-21-000014 · wf-form4_161074545857133.xml · nonDerivative · entry 9 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 896,641 F6 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F10 · price: This transaction was executed in multiple trades at prices ranging from $74.44 to $74.81, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:17 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 2,589 | $73.84 | $191,171.76 |
DisclosureSEC source: 0001447362-21-000014 · wf-form4_161074545857133.xml · nonDerivative · entry 8 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 897,252 F6 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F9 · price: This transaction was executed in multiple trades at prices ranging from $73.40 to $74.38, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:17 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 1,530 | $72.86 | $111,475.80 |
DisclosureSEC source: 0001447362-21-000014 · wf-form4_161074545857133.xml · nonDerivative · entry 7 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 899,841 F6 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F8 · price: This transaction was executed in multiple trades at prices ranging from $72.36 to $73.06, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:17 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 270 | $71.66 | $19,348.20 |
DisclosureSEC source: 0001447362-21-000014 · wf-form4_161074545857133.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 901,371 F6 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $71.35 to $72.32, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:17 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 100 | $76.78 | $7,678.00 |
DisclosureSEC source: 0001447362-21-000014 · wf-form4_161074545857133.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 901,641 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:17 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 603 | $74.52 | $44,935.56 |
DisclosureSEC source: 0001447362-21-000014 · wf-form4_161074545857133.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 901,741 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $74.41 to $74.61, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:17 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 5,118 | $73.96 | $378,527.28 |
DisclosureSEC source: 0001447362-21-000014 · wf-form4_161074545857133.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 902,344 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $73.40 to $74.37, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:17 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 3,156 | $72.94 | $230,198.64 |
DisclosureSEC source: 0001447362-21-000014 · wf-form4_161074545857133.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 907,462 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $72.40 to $73.36, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:17 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 400 | $71.36 | $28,544.00 |
DisclosureSEC source: 0001447362-21-000014 · wf-form4_161074545857133.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 910,618 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $71.17 to $71.52, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 12, 2021 Filed Jan 13, 2021 21:08 UTC |
Stokes FrankChief Financial Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 7,500 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001447362-21-000010 · wf-form4_161057206721913.xml · derivative · entry 10 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,137 Underlying: Common Stock · 7,500 shares Expires 2028-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 6, 2020. F8 · derivative.exercise_date: The option is exercisable immediately, in whole or in part, conditioned upon the Reporting Person entering into a restricted stock purchase agreement with respect to any unvested shares. 25% of the 133,137 shares originally subject to the option vested on December 4, 2018, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| January 12, 2021 Filed Jan 13, 2021 21:08 UTC |
Stokes FrankChief Financial Officer
|
SaleCommon Stock | 1,100 | $78.98 | $86,882.40 |
DisclosureSEC source: 0001447362-21-000010 · wf-form4_161057206721913.xml · nonDerivative · entry 8 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,886 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 6, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $78.850 to $79.155, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 12, 2021 Filed Jan 13, 2021 21:08 UTC |
Stokes FrankChief Financial Officer
|
SaleCommon Stock | 4,900 | $78.29 | $383,625.90 |
DisclosureSEC source: 0001447362-21-000010 · wf-form4_161057206721913.xml · nonDerivative · entry 7 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,986 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 6, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $77.770 to $78.730, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 12, 2021 Filed Jan 13, 2021 21:08 UTC |
Stokes FrankChief Financial Officer
|
SaleCommon Stock | 1,500 | $77.02 | $115,536.00 |
DisclosureSEC source: 0001447362-21-000010 · wf-form4_161057206721913.xml · nonDerivative · entry 6 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,886 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 6, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $76.625 to $77.310, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 12, 2021 Filed Jan 13, 2021 21:08 UTC |
Stokes FrankChief Financial Officer
|
Exercise / conversionCommon Stock | 7,500 | $2.39 | $17,925.00 |
DisclosureSEC source: 0001447362-21-000010 · wf-form4_161057206721913.xml · nonDerivative · entry 5 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,386 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 6, 2020. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 21:06 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 2,496 | $79.07 | $197,358.72 |
DisclosureSEC source: 0001447362-21-000012 · wf-form4_161065836982292.xml · nonDerivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 403,493 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $78.91 to $79.39, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 21:06 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 6,567 | $78.45 | $515,181.15 |
DisclosureSEC source: 0001447362-21-000012 · wf-form4_161065836982292.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 405,989 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $77.89 to $78.87, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 21:06 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 3,050 | $77.32 | $235,826.00 |
DisclosureSEC source: 0001447362-21-000012 · wf-form4_161065836982292.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 412,556 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $76.86 to $77.85, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 21:08 UTC |
Stokes FrankChief Financial Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 7,500 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001447362-21-000010 · wf-form4_161057206721913.xml · derivative · entry 9 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,637 Underlying: Common Stock · 7,500 shares Expires 2028-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 6, 2020. F8 · derivative.exercise_date: The option is exercisable immediately, in whole or in part, conditioned upon the Reporting Person entering into a restricted stock purchase agreement with respect to any unvested shares. 25% of the 133,137 shares originally subject to the option vested on December 4, 2018, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 21:08 UTC |
Stokes FrankChief Financial Officer
|
SaleCommon Stock | 200 | $79.26 | $15,851.60 |
DisclosureSEC source: 0001447362-21-000010 · wf-form4_161057206721913.xml · nonDerivative · entry 4 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,886 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 6, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $79.255 to $79.260, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 21:08 UTC |
Stokes FrankChief Financial Officer
|
SaleCommon Stock | 6,000 | $78.17 | $469,020.00 |
DisclosureSEC source: 0001447362-21-000010 · wf-form4_161057206721913.xml · nonDerivative · entry 3 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,086 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 6, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $78.000 to $78.600, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 21:08 UTC |
Stokes FrankChief Financial Officer
|
SaleCommon Stock | 1,300 | $77.35 | $100,555.00 |
DisclosureSEC source: 0001447362-21-000010 · wf-form4_161057206721913.xml · nonDerivative · entry 2 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,086 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 6, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $76.950 to $77.790, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 21:08 UTC |
Stokes FrankChief Financial Officer
|
Exercise / conversionCommon Stock | 7,500 | $2.39 | $17,925.00 |
DisclosureSEC source: 0001447362-21-000010 · wf-form4_161057206721913.xml · nonDerivative · entry 1 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,386 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 6, 2020. Read SEC document |
| December 30, 2020 Filed Dec 31, 2020 21:07 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 100 | $69.72 | $6,972.00 |
DisclosureSEC source: 0001447362-20-000305 · wf-form4_160944885212811.xml · nonDerivative · entry 11 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,257,252 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. Read SEC document |
| December 30, 2020 Filed Dec 31, 2020 21:07 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 5,645 | $69.02 | $389,634.84 |
DisclosureSEC source: 0001447362-20-000305 · wf-form4_160944885212811.xml · nonDerivative · entry 10 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,257,352 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F10 · price: This transaction was executed in multiple trades at prices ranging from $68.680 to $69.600, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 30, 2020 Filed Dec 31, 2020 21:07 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 9,255 | $68.33 | $632,431.17 |
DisclosureSEC source: 0001447362-20-000305 · wf-form4_160944885212811.xml · nonDerivative · entry 9 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,262,997 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F9 · price: This transaction was executed in multiple trades at prices ranging from $67.660 to $68.650, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 29, 2020 Filed Dec 30, 2020 21:36 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 100 | $74.71 | $7,470.50 |
DisclosureSEC source: 0001447362-20-000303 · wf-form4_160936418004132.xml · nonDerivative · entry 12 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 731,191 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| December 29, 2020 Filed Dec 30, 2020 21:36 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 200 | $73.33 | $14,665.80 |
DisclosureSEC source: 0001447362-20-000303 · wf-form4_160936418004132.xml · nonDerivative · entry 11 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 731,291 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F13 · price: This transaction was executed in multiple trades at prices ranging from $72.900 to $73.710, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| December 29, 2020 Filed Dec 30, 2020 21:36 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 215 | $71.47 | $15,365.41 |
DisclosureSEC source: 0001447362-20-000303 · wf-form4_160936418004132.xml · nonDerivative · entry 10 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 731,491 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F12 · price: This transaction was executed in multiple trades at prices ranging from $71.425 to $72.000, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| December 29, 2020 Filed Dec 30, 2020 21:36 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 500 | $70.33 | $35,166.50 |
DisclosureSEC source: 0001447362-20-000303 · wf-form4_160936418004132.xml · nonDerivative · entry 9 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 731,706 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F11 · price: This transaction was executed in multiple trades at prices ranging from $70.100 to $71.090, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| December 29, 2020 Filed Dec 30, 2020 21:36 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 200 | $69.11 | $13,821.00 |
DisclosureSEC source: 0001447362-20-000303 · wf-form4_160936418004132.xml · nonDerivative · entry 8 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 732,206 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F10 · price: This transaction was executed in multiple trades at prices ranging from $69.100 to $69.110, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| December 29, 2020 Filed Dec 30, 2020 21:36 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 805 | $67.63 | $54,442.15 |
DisclosureSEC source: 0001447362-20-000303 · wf-form4_160936418004132.xml · nonDerivative · entry 7 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 732,406 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F9 · price: This transaction was executed in multiple trades at prices ranging from $67.485 to $68.210, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.